All In Biotech

Drug Trial Radar · NCT06404905

Clinical Trial of BT02 in Patients With Advanced Solid Tumors

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 24, 2024

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Academic, hospital or other
First posted
May 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor

Interventions

  • BT02 monoclonal antibody injectionDrug

    It is expected to include 10-30 patients assigned to dose escalation cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting ToxicityTime frame: Within day 28 after administration
  2. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Within day 28 after administration
  3. Maximum tolerated doseTime frame: Within day 28 after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital

    Beijing, Biejing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.